ES2172415B2 - Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. - Google Patents

Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Info

Publication number
ES2172415B2
ES2172415B2 ES200001916A ES200001916A ES2172415B2 ES 2172415 B2 ES2172415 B2 ES 2172415B2 ES 200001916 A ES200001916 A ES 200001916A ES 200001916 A ES200001916 A ES 200001916A ES 2172415 B2 ES2172415 B2 ES 2172415B2
Authority
ES
Spain
Prior art keywords
glaucoma
treatment
ocular hypertension
analog
melatonine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200001916A
Other languages
English (en)
Other versions
ES2172415A1 (es
Inventor
Just Jesus Pintor
Cerda Asuncion Peral
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES200001916A priority Critical patent/ES2172415B2/es
Priority to US09/915,486 priority patent/US6730707B2/en
Priority to EP01959427A priority patent/EP1307191A2/en
Priority to CN01815096A priority patent/CN1450896A/zh
Priority to AU2001280984A priority patent/AU2001280984A1/en
Priority to ARP010103596A priority patent/AR035651A1/es
Priority to CA002417489A priority patent/CA2417489A1/en
Priority to PCT/US2001/024220 priority patent/WO2002009702A2/en
Priority to KR10-2003-7001250A priority patent/KR20030046395A/ko
Priority to JP2002515255A priority patent/JP2004518612A/ja
Priority to MXPA03000729A priority patent/MXPA03000729A/es
Publication of ES2172415A1 publication Critical patent/ES2172415A1/es
Application granted granted Critical
Publication of ES2172415B2 publication Critical patent/ES2172415B2/es
Priority to US10/828,785 priority patent/US20040198803A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tratamiento del glaucoma y la hipertensión ocular por medio de un análogo de la melatonina. La presente invención describe un método para el tratamiento de la hipertensión ocular y del glaucoma mediante la administración de la sustancia comercial 5- metoxicarbonilamino-N-acetiltriptamina (5-MCA-NAT). La solución es aplicada preferentemente por vía tópica, pudiendo ser aplicada por medio de otros tipos de preparados como gotas de líquido, lavados de líquido, geles, ungüentos, sprays y liposomas.
ES200001916A 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. Expired - Fee Related ES2172415B2 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200001916A ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US09/915,486 US6730707B2 (en) 2000-07-28 2001-07-25 Method for reducing intraocular pressure using indole derivatives
JP2002515255A JP2004518612A (ja) 2000-07-28 2001-07-27 インドール誘導体を用いて眼圧を下降させる方法
AU2001280984A AU2001280984A1 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
ARP010103596A AR035651A1 (es) 2000-07-28 2001-07-27 Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
CA002417489A CA2417489A1 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP01959427A EP1307191A2 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
KR10-2003-7001250A KR20030046395A (ko) 2000-07-28 2001-07-27 인돌 유도체를 사용하여 안압을 감소시키는 방법
CN01815096A CN1450896A (zh) 2000-07-28 2001-07-27 用吲哚衍生物降低眼内压的方法
MXPA03000729A MXPA03000729A (es) 2000-07-28 2001-07-27 Metodo para reducir la presion intraocular utilizando derivados de indol.
PCT/US2001/024220 WO2002009702A2 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
US10/828,785 US20040198803A1 (en) 2000-07-28 2004-04-20 Method for reducing intraocular pressure using indole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001916A ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Publications (2)

Publication Number Publication Date
ES2172415A1 ES2172415A1 (es) 2002-09-16
ES2172415B2 true ES2172415B2 (es) 2003-11-16

Family

ID=8494491

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001916A Expired - Fee Related ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Country Status (2)

Country Link
US (2) US6730707B2 (es)
ES (1) ES2172415B2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
JP4619786B2 (ja) * 2002-08-29 2011-01-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性、アレルギー性及び増殖性疾患の治療において糖質コルチコイドミメティックスとして使用するための３−（スルホンアミドエチル）−インドール誘導体
JP3964417B2 (ja) * 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
US20090220516A1 (en) * 2005-06-22 2009-09-03 Alan Laties Neuroprotection of retinal ganglion cells
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
CA2728623A1 (en) * 2008-06-24 2010-01-21 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
RS58718B1 (sr) 2011-05-12 2019-06-28 Proteostasis Therapeutics Inc Regulatori proteostaze
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
KR101651448B1 (ko) 2012-11-21 2016-08-26 토포카인 쎄라퓨틱스, 인코포레이티드 체지방을 국소적으로 증가시키는 방법 및 조성물
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
NO2753788T3 (es) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
EP3907231A1 (en) * 2015-07-19 2021-11-10 Yeda Research and Development Co., Ltd. Selective inhibitors of alpha2-containing isoforms of na,k-atpase and use thereof for reducing intraocular pressure
IL301028A (en) * 2020-09-02 2023-05-01 Enveric Biosciences Canada Inc Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2023044556A1 (en) * 2021-09-24 2023-03-30 Enveric Biosciences Canada Inc. Aminated psilocybin derivatives and methods of using
CN113880749B (zh) * 2021-10-11 2023-06-30 江南大学 化合物JNc-463的制备方法及其应用
WO2025099444A1 (en) * 2023-11-09 2025-05-15 Beckley Psytech Limited N-Acetylserotonin (NAS) Analogues

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393081A (en) * 1981-10-28 1983-07-12 Miles Laboratories, Inc. Methyl 3-acetamido-2-(5-methoxy-indol-3-yl) propanoate and hypotensive use thereof
US4803218A (en) 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
FI900801A7 (fi) * 1987-08-17 1990-02-16 Nelson Res & Development Co Melantoniinianalogit
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US6071946A (en) 1994-10-21 2000-06-06 Adir Et Compagnie Tricyclic urea compounds
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2737725B1 (fr) 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
AU1698899A (en) * 1997-11-04 1999-05-24 St. Elizabeth's Medical Center Of Boston, Inc. N-acetylserotonin derivatives and uses thereof
KR20010034461A (ko) * 1998-01-28 2001-04-25 요시다 쇼지 시기능 장해의 예방 또는 치료제
EP1096975B1 (en) 1998-07-16 2005-03-16 The Trustees Of The University Of Pennsylvania Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.

Also Published As

Publication number Publication date
US20040198803A1 (en) 2004-10-07
ES2172415A1 (es) 2002-09-16
US20020037887A1 (en) 2002-03-28
US6730707B2 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
ES2157424T3 (es) Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
UY28150A1 (es) Agentes terapeuticos
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
BR9911068A (pt) Terapia combinada para tratamento de distúrbios bipolares
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
BR0309499A (pt) Derivados de [1,4]diazocino[7,8,1-hi]indol como agentes antipsicóticos e antiobesidade
TR199801164T2 (xx) S�bstit�e edilmi� tetrasiklik tetrahidrofuran t�revleri.
BR0115080A (pt) Derivados de acila e sulfonila de 2-(trans-1,4-diaminocicloexil)-purinas 6,9-dissubstituìdas e o uso destes como agentes antiproliferativos
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
DE69232942D1 (de) Produkte zur behandlung von glaukoma
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
UY26426A1 (es) Nuevos compuestos
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
PE20011260A1 (es) Derivados de sulfonamida
ATE402704T1 (de) Dopamin-d3-rezeptor-liganden zur behandlung von sucht
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020916

Kind code of ref document: A1

Effective date: 20020916

FG2A Definitive protection

Ref document number: 2172415B2

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20201105